A Face to Face episode covering how the drugs act in the body plus their benefits and risks, with a full replay on YouTube.
Recap by typeshit. Post by Facebook on Facebook.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Chromatography specialists explain how peptides stick to vials and tubing, and why non-inert column hardware showed much lower recovery in one comparison.
The cardiothoracic surgeon covers the newly published New England Journal of Medicine results from Lilly's phase 3 retatrutide trial.
Loading…